Wingard M, Merz WG. Binaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutroponia treated prophylactically with fluconazole[J]. N Earl J Med, 1991, 325(17): 1274-1277.
[2]
Krtiger WH, Riissmann B, de Wit M, et al. Haemopoietie cell transplantation of patients witll a history of deep or invasive funsal infection during prophylaxis with lipesomal amphoteriein B[J]. Acts Haematol, 2005, 113(42): 104-108.
[3]
Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits[J]. Antimicrob Agents Chemother, 2002, 46(26): 1857-1869.
[4]
David WD, Kieren AM, Wendi ML, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis[J]. J Infect, 2006, 53(12): 337-349.
[5]
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 46(11): 327-360.
[6]
Fukuda T, Boecldl M,, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietie stem cell transplantation: 10-year experience at a single transphnt center[J]. Biol Blood Marrow Transplant, 2004, 10(13): 494-503.
Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transp lantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious comp lications and changes over calendar time[J]. Bone Marrow Transplant, 2005, 36(11): 757-769.
[9]
Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing asperlllosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies[J]. Clin Infect Dis, 2006, 42(9): 1584-1591.
van Burik JA, Ratanatharathorn V, Stepan DE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation[J]. Clin Infect Dis, 2004, 39(10): 1407-1416.
Herbreeht R, Denning DW, Patterson V, et al. Voriconazole versus amphotericin B for primary thempy of invasive aspergillosis[J]. N Ensl J Med, 2002, 347(18): 408-415.
[14]
Madureira A, Bergemn A, Lacroix C, et al. Breakthrough invasive aspergiIlosis in allogeneic haematopoietic stem cell transplant recipients treated with easpofungin[J]. Int J Antimiemb Agents, 2007, 30(7): 551-554.
